239 related articles for article (PubMed ID: 9187194)
1. Noninvasive detection of atherosclerotic lesions by 99mTc-based immunoscintigraphic targeting of proliferating smooth muscle cells.
Narula J; Petrov A; Pak KY; Ditlow C; Chen F; Khaw BA
Chest; 1997 Jun; 111(6):1684-90. PubMed ID: 9187194
[TBL] [Abstract][Full Text] [Related]
2. Gamma imaging of atherosclerotic lesions: the role of antibody affinity in in vivo target localization.
Narula J; Petrov A; O'Donnell SM; Ditlow C; Pieslak I; Dilley J; Chen F; Khaw BA
J Nucl Cardiol; 1996; 3(3):231-41. PubMed ID: 8805743
[TBL] [Abstract][Full Text] [Related]
3. Noninvasive localization of experimental atherosclerotic lesions with mouse/human chimeric Z2D3 F(ab')2 specific for the proliferating smooth muscle cells of human atheroma. Imaging with conventional and negative charge-modified antibody fragments.
Narula J; Petrov A; Bianchi C; Ditlow CC; Lister BC; Dilley J; Pieslak I; Chen FW; Torchilin VP; Khaw BA
Circulation; 1995 Aug; 92(3):474-84. PubMed ID: 7634463
[TBL] [Abstract][Full Text] [Related]
4. Maximizing radiotracer delivery to experimental atherosclerotic lesions with high-dose, negative charge-modified Z2D3 antibody for immunoscintigraphic targeting.
Narula J; Petrov A; Ditlow C; Pak KY; Chen FW; Khaw BA
J Nucl Cardiol; 1997; 4(3):226-33. PubMed ID: 9199260
[TBL] [Abstract][Full Text] [Related]
5. Noninvasive localization of human atherosclerotic lesions with indium 111-labeled monoclonal Z2D3 antibody specific for proliferating smooth muscle cells.
Carrió I; Pieri PL; Narula J; Prat L; Riva P; Pedrini L; Pretolani E; Caruso G; Sarti G; Estorch M; Berná L; Riambau V; Matías-Guiu X; Pak C; Ditlow C; Chen F; Khaw BA
J Nucl Cardiol; 1998; 5(6):551-7. PubMed ID: 9869476
[TBL] [Abstract][Full Text] [Related]
6. Reduction of background activity through radiolabeling of antifibrin Fab' with 99mTc-dextran.
Line BR; Weber PB; Lukasiewicz R; Dansereau RN
J Nucl Med; 2000 Jul; 41(7):1264-70. PubMed ID: 10914920
[TBL] [Abstract][Full Text] [Related]
7. Targeting arterial wall sulfated glycosaminoglycans in rabbit atherosclerosis with a mouse/human chimeric antibody.
Soto Y; Mesa N; Alfonso Y; Pérez A; Batlle F; Griñán T; Pino A; Viera J; Frómeta M; Brito V; Olivera A; Zayas F; Vázquez AM
MAbs; 2014; 6(5):1340-6. PubMed ID: 25517318
[TBL] [Abstract][Full Text] [Related]
8. Imaging experimental atherosclerotic lesions in ApoE knockout mice: enhanced targeting with Z2D3-anti-DTPA bispecific antibody and 99mTc-labeled negatively charged polymers.
Khaw BA; Tekabe Y; Johnson LL
J Nucl Med; 2006 May; 47(5):868-76. PubMed ID: 16644758
[TBL] [Abstract][Full Text] [Related]
9. Radiolabeled MDA2, an oxidation-specific, monoclonal antibody, identifies native atherosclerotic lesions in vivo.
Tsimikas S; Palinski W; Halpern SE; Yeung DW; Curtiss LK; Witztum JL
J Nucl Cardiol; 1999; 6(1 Pt 1):41-53. PubMed ID: 10070840
[TBL] [Abstract][Full Text] [Related]
10. Targeting human breast tumour in xeno-grafted SCID mice with 99Tcm-glucarate.
Petrov AD; Narula J; Nakazawa A; Pak KY; Khaw BA
Nucl Med Commun; 1997 Mar; 18(3):241-51. PubMed ID: 9106778
[TBL] [Abstract][Full Text] [Related]
11. Targeting of liver metastases of colorectal cancer with IgG, F(ab')2, and Fab' anti-carcinoembryonic antigen antibodies labeled with 99mTc: the role of metabolism and kinetics.
Behr T; Becker W; Hannappel E; Goldenberg DM; Wolf F
Cancer Res; 1995 Dec; 55(23 Suppl):5777s-5785s. PubMed ID: 7493346
[TBL] [Abstract][Full Text] [Related]
12. Initial clinical results with technetium-99m-labeled LL2 monoclonal antibody fragment in the radioimmunodetection of B-cell lymphomas.
Baum RP; Niesen A; Hertel A; Adams S; Kojouharoff G; Goldenberg DM; Hör G
Cancer; 1994 Feb; 73(3 Suppl):896-9. PubMed ID: 8306276
[TBL] [Abstract][Full Text] [Related]
13. Development of receptor for advanced glycation end products-directed imaging of atherosclerotic plaque in a murine model of spontaneous atherosclerosis.
Tekabe Y; Li Q; Rosario R; Sedlar M; Majewski S; Hudson BI; Einstein AJ; Schmidt AM; Johnson LL
Circ Cardiovasc Imaging; 2008 Nov; 1(3):212-9. PubMed ID: 19808545
[TBL] [Abstract][Full Text] [Related]
14. Safety, pharmacokinetic and dosimetry evaluation of the proposed thrombus imaging agent 99mTc-DI-DD-3B6/22-80B3 Fab'.
Macfarlane DJ; Smart RC; Tsui WW; Gerometta M; Eisenberg PR; Scott AM
Eur J Nucl Med Mol Imaging; 2006 Jun; 33(6):648-56. PubMed ID: 16528525
[TBL] [Abstract][Full Text] [Related]
15. Radioimmunodetection of colorectal carcinoma using technetium-99m-labeled Fab' fragments of the IMMU-4 anti-carcinoembryonic antigen monoclonal antibody.
Moffat FL; Vargas-Cuba RD; Serafini AN; Casillas VJ; Morillo G; Benedetto P; Robinson DS; Ardalan B; Manten HD; Clark KC
Cancer; 1994 Feb; 73(3 Suppl):836-45. PubMed ID: 8306268
[TBL] [Abstract][Full Text] [Related]
16. Imaging of deep venous thrombosis in patients using a radiolabelled anti-D-dimer Fab' fragment (99mTc-DI-DD3B6/22-80B3): results of a phase I trial.
Macfarlane D; Socrates A; Eisenberg P; Larcos G; Roach P; Gerometta M; Smart R; Tsui W; Scott AM
Eur J Nucl Med Mol Imaging; 2009 Feb; 36(2):250-9. PubMed ID: 18800218
[TBL] [Abstract][Full Text] [Related]
17. Targeting of lectinlike oxidized low-density lipoprotein receptor 1 (LOX-1) with 99mTc-labeled anti-LOX-1 antibody: potential agent for imaging of vulnerable plaque.
Ishino S; Mukai T; Kuge Y; Kume N; Ogawa M; Takai N; Kamihashi J; Shiomi M; Minami M; Kita T; Saji H
J Nucl Med; 2008 Oct; 49(10):1677-85. PubMed ID: 18794262
[TBL] [Abstract][Full Text] [Related]
18. Imaging of HER2/neu expression in BT-474 human breast cancer xenografts in athymic mice using [(99m)Tc]-HYNIC-trastuzumab (Herceptin) Fab fragments.
Tang Y; Scollard D; Chen P; Wang J; Holloway C; Reilly RM
Nucl Med Commun; 2005 May; 26(5):427-32. PubMed ID: 15838425
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT.
Gainkam LO; Huang L; Caveliers V; Keyaerts M; Hernot S; Vaneycken I; Vanhove C; Revets H; De Baetselier P; Lahoutte T
J Nucl Med; 2008 May; 49(5):788-95. PubMed ID: 18413403
[TBL] [Abstract][Full Text] [Related]
20. Experimental pretargeting studies of cancer with a humanized anti-CEA x murine anti-[In-DTPA] bispecific antibody construct and a (99m)Tc-/(188)Re-labeled peptide.
Karacay H; McBride WJ; Griffiths GL; Sharkey RM; Barbet J; Hansen HJ; Goldenberg DM
Bioconjug Chem; 2000; 11(6):842-54. PubMed ID: 11087333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
